Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Mittelman

Showing results (91-100 of 114) with videos related to

Pageof 12
Sort By:
Haematologica|April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS RegistryBente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
British Journal of Haematology|February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategiesAleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Journal of Clinical Medicine|September 28, 2023
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin LevelYael Haring, Noa Goldschmidt, Shaimaa Taha, et al.
American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
European Journal of Haematology|May 13, 2014
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 studyAristoteles Giagounidis, Ghulam J Mufti, Moshe Mittelman, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Pageof 12

Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Haematologica|April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS RegistryBente Houtman, Adele Taylor, Corine Van Marrewijk, et al.
British Journal of Haematology|February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategiesAleksandar Savic, Adele Taylor, Pierre Fenaux, et al.
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Journal of Clinical Medicine|September 28, 2023
MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin LevelYael Haring, Noa Goldschmidt, Shaimaa Taha, et al.
American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
British Journal of Haematology|November 6, 2022
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registryKrzysztof Mądry, Karol Lis, Pierre Fenaux, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
European Journal of Haematology|May 13, 2014
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 studyAristoteles Giagounidis, Ghulam J Mufti, Moshe Mittelman, et al.
Blood|July 15, 2011
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qPierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Pageof 12